Stem Cell Transplants in Childhood Neuroblastoma Improves Immunotherapy Outcomes
A recently published study in the Journal of Clinical Oncology points to improved outcomes from Cancer Immunotherapy (dinutuximab beta) following Stem Cell Transplantation from parent donors. 5 year survival exceeded 50% compared to 23% with traditional treatments. The additional benefit from the Stem Cell Transplantation likely resides in the formation of new Natural Killer cells in the recipient which appears to augment the Immunotherapy agent.
Search our Directory
AABRM Members are not only experts in regenerative medicine but offer a wide range of related products, services and related-procedures in that field. Search our extensive Member Directory to find a Member near you.Member Directory